ABBV Earnings Date: Feb 3, 2027 (Estimated) — AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General
Updated
When is ABBV's next earnings date?
AbbVie Inc. (ABBV) is expected to report Q4 2026 earnings on Wednesday, February 3, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $3.89 on revenue of $18.31B.
How did ABBV do in its last earnings report?
In its most recent report on Oct 30, 2026 (Q3 2026), AbbVie Inc. posted EPS of $3.82 versus the $3.73 estimate, a beat of 2.4%. Revenue was $17.40B against a $17.32B estimate.
How much does ABBV stock move after earnings?
ABBV beat EPS estimates in 5 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 3.1% (up or down) in the day after earnings.
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
🤖 AI Earnings Analysis
AbbVie’s Q3 was strong: adjusted EPS rose 105% to $3.82, beating estimates by $0.09, while revenue grew 10% to $17.4B; its $13.76–$13.96 full-year EPS outlook reinforces momentum, though top-line growth remains more measured.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | Q3 2026 | 3.73 | 3.82 | +2.41% | $17.40B | ✅ Beat | — | — | — |
| 2026-07-31 | Q2 2026 | 3.77 | 3.65 | -3.18% | $16.99B | ❌ Miss | -2.51% | -5.26% | -0.75% |
| 2026-04-29 | Q1 2026 | 2.66 | 2.65 | -0.38% | $15.00B | ❌ Miss | +3.14% | +4.26% | +10.59% |
| 2026-02-04 | Q4 2025 | 2.66 | 2.71 | +1.88% | $16.62B | ✅ Beat | -3.79% | -1.43% | +2.97% |
| 2025-10-31 | Q3 2025 | 1.78 | 1.86 | +4.49% | $15.78B | ✅ Beat | -4.45% | -4.01% | -1.35% |
| 2025-07-31 | Q2 2025 | 2.90 | 2.97 | +2.41% | $15.42B | ✅ Beat | -0.15% | +3.69% | +9.83% |
| 2025-04-25 | Q1 2025 | 2.38 | 2.46 | +3.36% | $13.34B | ✅ Beat | +3.16% | +7.20% | +1.60% |
| 2025-01-31 | Q4 2024 | 2.26 | 2.16 | -4.42% | $15.10B | ❌ Miss | +4.70% | +9.86% | +20.40% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $16.04B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| SKYRIZI | 34.3% | $5.50B | +24.5% | $3.78B | $3.42B | $4.42B | $4.71B |
| RINVOQ | 15.7% | $2.52B | +24.5% | $1.83B | $1.72B | $2.03B | $2.18B |
| Other Products | 6.9% | $1.11B | +83.9% | $752.0M | $747.0M | $603.0M | $660.0M |
| Vraylar | 6.7% | $1.07B | +19.0% | $924.0M | $765.0M | $900.0M | $934.0M |
| Botox Therapeutic | 6.5% | $1.04B | +12.3% | $873.0M | $866.0M | $928.0M | $985.0M |
| VENCLEXTA | 4.8% | $771.0M | +11.6% | $655.0M | $665.0M | $691.0M | $726.0M |
| H U M I R A | 4.7% | $756.0M | -35.9% | $1.68B | $1.12B | $1.18B | $993.0M |
By region
Q2 FY26 · $5.53B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 86.2% | $4.77B | +24.0% | $11.73B | $3.36B | $3.84B | $4.23B |
| Non-US | 13.8% | $760.0M | +31.0% | $3.37B | $9.98B | $580.0M | $625.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.